Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Nederlandsche Gist-en Spiritusfabriek (NG&SF), established in 1869 by Jacques van Marken in Delft, was a foundational entity in the global biotechnology and fermentation industries. Originally a producer of yeast and spirits, the company gained international prominence for its secret development of penicillin (under the code name Bacinol) during the German occupation of the Netherlands in World War II. Following the war, it became one of the world's largest manufacturers of penicillin and other essential antibiotics. In 1967, the company merged with Brocades-Stheeman & Pharmacia to form Gist-brocades, significantly expanding its pharmaceutical footprint. Gist-brocades was eventually acquired by the Dutch multinational DSM in 1998 for approximately $1.3 billion. Today, the legacy of NG&SF persists within dsm-firmenich, particularly in the production of anti-infectives and food enzymes.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Nederlandsche Gist-en Spiritusfabriek.